Washington Appeals Court Rejects New Learned Intermediary Rule In Lamictal Case

Washington Appeals Court Rejects New Learned Intermediary Rule In Lamictal Case

SEATTLE - A Washington state appellate panel on Sept. 9 declined to adopt a new learned intermediary standard that would require drug makers to inform all doctors, not just treating physicians, that a prescription drug can cause a rare, life-threatening skin and tissue reaction (David A. Falsberg v. GlaxoSmithKline, PLC, et al., No. 68264-4-I, Wash. App., Div. 1).

Find full version on lexis Advance®
Access this news story on lexis.com®